Cytokinetics pharmaceuticals logo
WebOct 27, 2024 · Cytokinetics hopes to launch omecamtiv mecarbil and aficamten, along with a third drug dubbed reldesemtiv, over the next three years. Reldesemtiv is in testing for amyotrophic lateral sclerosis,... WebMar 6, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
Cytokinetics pharmaceuticals logo
Did you know?
WebDec 13, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal... WebFeb 4, 2024 · CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contacts: …
WebApr 11, 2024 · MGC Pharmaceuticals logo MGC Pharma's CannEpil® is an investigational medicinal product (IMP) designed for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy.... Web $14,232
Web12 hours ago · Cytokinetics (CYTK) In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed … http://news.mnbkw.com/go/109810.html
WebAddress ., 280 East Grand Avenue, South San Francisco, California, 94080 Website cytokinetics.com Telephone 1 650 6243000 No of Employees 253 Industry Pharmaceuticals and Healthcare Ticker Symbol & Exchange CYTK (NASD) Revenue (2024) $70.4M 26.2% (2024 vs 2024) EPS XXX Net Income (2024) XXX -69.2% (2024 …
WebNov 30, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the company’s New Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin … deserted lighthousesWebDec 23, 2024 · Cytokinetics (CYTK) Gets a Buy from Needham TipRanks Dec. 23, 2024, 06:25 AM Needham analyst Serge Belanger maintained a Buy rating on Cytokinetics ( CYTK – Research Report) today and set a... deserted locationsWebApr 10, 2024 · CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Communications, Investor Relations (415) 290-7757 You just read: cht joinery newportWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 … deserted soccer fieldWebApr 10, 2024 · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. About the company Rewards Revenue is forecast to grow 46.65% per year Risk Analysis Negative shareholders equity deserted military termWebMar 31, 2024 · Cytokinetics' heart disease drug, aficamten, is a "crown jewel in terms of the pipeline", said Oppenheimer analyst Justin Kim, who expects it could bring more than $1 billion in peak sales from U ... cht lab handbookWebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of 4.7%. chtlamp